Sanofi (NASDAQ: SNY) Reports Q2 2026 Earnings Thursday July 30 With Net Sales of €11.6 Billion (+17.8% at Constant Exchange Rates) Driven by Dupixent (+37.6% CER to €5.15 Billion) and New Pharma Launches (+48.3% CER to €1.3 Billion), Business EPS of €2.09 (+33.3% CER); Sanofi Discontinues Three Pipeline Assets in the Quarter (Amlitelimab OX40-Ligand mAb for Atopic Dermatitis With a €952 Million Intangible Impairment, Plus Itepekimab and Balinatunfib) and Raises Full-Year 2026 Guidance to Approximately 10% CER Sales Growth With Business EPS Growing Slightly Faster
Sanofi (NASDAQ: SNY) reported Q2 2026 earnings Thursday July 30, 2026 with net sales of €11,597 million (+17.8% at constant exchange rates, +16.0% at actual rates) and business EPS of €2.09 (+33.3% CER), both beating consensus. Growth drivers: Dupixent (dupilumab, IL-4/IL-13 receptor blocking antibody co-marketed with Regeneron) reached Q2 sales of €5,154 million (+37.6% CER); new pharma launches reached €1,305 million (+48.3% CER). Sanofi raised full-year 2026 guidance: sales now expected to grow approximately 10% at CER, with business EPS at CER expected to grow slightly faster than sales. Three pipeline discontinuations disclosed with the earnings release: amlitelimab (OX40-ligand monoclonal antibody previously advanced in atopic dermatitis after acquisition from Kymab; the intangible asset was impaired by €952 million with an announced decision that the drug would not represent a substantial improvement to the standard of care), itepekimab (IL-33 antibody previously advanced in COPD, chronic urticaria, and other Type 2 inflammation indications), and balinatunfib. Stock reaction was mixed with Sanofi shares slipping in premarket trading on the pipeline setbacks despite the earnings beat.